Monograph
M05BX03 - Strontium Ranelate |
Not porphyrinogenic |
NP |
Rationale
Strontium ranelate is not metabolised and does not inhibit or induce CYP450 enzymes.
Risk for gastrointestinal adverse events in the form of nausea and diarrhoea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Therapeutic characteristics
Strontium ranelate is indicated for the treatment of osteoporosis.
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, diarrhoea and loose stools.
Metabolism and pharmacokinetics
Stronitum is a divalent cation and is not metabolised. It does not inhibit CYP450 enzymes (SPC).
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Strontium ranelate.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Osseor 
Osseor · Protelos · Ranelato Estroncio 
Protelos · Strontium ranelate 
Protelos 
Osseor · Protelos
© NAPOS 2025